Meeting
2020 Genitourinary Cancers Symposium
Disulfiram (DSF) pharmacokinetics (PK) and copper PET imaging in a phase Ib study of intravenous (IV) copper loading with oral DSF for patients with metastatic castration-resistant prostate cancer (mCRPC).
Authors
Tian Zhang
Duke Cancer Institute, Durham, NC
Tian Zhang , Julie Kephart , Elizabeth Bronson , Monika Anand , Christine Daly , Ivan Spasojevic , Hannah Berg , Olga G. James , Patrick Healy , Susan Halabi , Michael Roger Harrison , Andrew J. Armstrong , Daniel J. George
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A: Prostate Cancer
Track
Prostate Cancer - Advanced,Prostate Cancer - Localized
Sub Track
Therapeutics
Clinical Trial Registration Number
NCT02963051
Citation
J Clin Oncol 38, 2020 (suppl 6; abstr 96)
Abstract #
96
Poster Bd #
D20
Abstract Disclosures
Similar Posters
Poster
2019 Genitourinary Cancers Symposium
A phase III trial of docetaxel versus docetaxel and radium-223 (Ra-223) in patients with metastatic castration-resistant prostate cancer (mCRPC): DORA.
First Author: Michael J. Morris
Poster
2023 ASCO Genitourinary Cancers Symposium
A phase 1/2 study of REGN4336, a PSMAxCD3 bispecific antibody, alone and in combination with cemiplimab in patients with metastatic castration-resistant prostate cancer.
First Author: William Kevin Kelly
Poster
2022 ASCO Annual Meeting
177Lu-DOTA-TLX591 safety, biodistribution and dosimetry study (ProstACT-SELECT).
First Author: Paola Antonini
Poster
2022 ASCO Genitourinary Cancers Symposium
BXCL701: First-in-class oral activator of systemic innate immunity combined with pembrolizumab, in patients with metastatic castration-resistant prostate cancer (mCRPC) of adenocarcinoma phenotype—Phase 2a results.
First Author: Jingsong Zhang